UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

Frontiers in oncology, 2020-05, Vol.10, p.817-817

2020

Volltextzugriff (PDF)

Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer

Cancer Immunology, Immunotherapy, 2021-06, Vol.70 (6), p.1735-1743

2021

Volltextzugriff (PDF)

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19

Gerontology (Basel), 2020-12, Vol.66 (6), p.553-561

2020

Volltextzugriff (PDF)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Frontiers in pharmacology, 2017-06, Vol.8, p.382

2017

Volltextzugriff (PDF)

An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases

Immunotherapy, 2021-03, Vol.13 (4), p.289-295

2021

Volltextzugriff (PDF)

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Immunity & ageing, 2020-11, Vol.17 (1), p.1-34, Article 34

2020

Volltextzugriff (PDF)

Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti–Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non–Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine

Clinical cancer research, 2008-02, Vol.14 (3), p.840-846

2008

Volltextzugriff (PDF)

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Frontiers in oncology, 2022-08, Vol.12, p.958043-958043

2022

Volltextzugriff (PDF)

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

Oncoimmunology, 2020-01, Vol.9 (1), p.1762465-1762465

2020

Volltextzugriff (PDF)

Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Frontiers in oncology, 2022-01, Vol.12, p.823287-823287

2022

Volltextzugriff (PDF)

Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

Frontiers in pharmacology, 2017-05, Vol.8, p.263-263

2017

Volltextzugriff (PDF)

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab

Clinical & translational immunology, 2020, Vol.9 (11), p.e1218-n/a

2020

Volltextzugriff (PDF)

Nimotuzumab: beyond the EGFR signaling cascade inhibition

Seminars in oncology, 2018-01, Vol.45 (1-2), p.18-26

2018

Volltextzugriff (PDF)

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients

Human vaccines, 2010-09, Vol.6 (9), p.736-744

2010

Volltextzugriff (PDF)

Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model

Clinical cancer research, 2006-12, Vol.12 (23), p.7092-7098

2006

Volltextzugriff (PDF)

CIMAvax-EGF: Toward long-term survival of advanced NSCLC

Seminars in oncology, 2018-01, Vol.45 (1-2), p.34-40

2018

Volltextzugriff (PDF)

Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients

Cancer Immunology, Immunotherapy, 2014-07, Vol.63 (7), p.737-747

2014

Volltextzugriff (PDF)

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Cancer Immunology, Immunotherapy, 2016-01, Vol.65 (1), p.37-45

2016

Volltextzugriff (PDF)

Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT130-CT130

2020

Volltextzugriff (PDF)

Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly

Experimental gerontology, 2019-09, Vol.124, p.110633-110633, Article 110633

2019

Volltextzugriff (PDF)

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

Clinical cancer research, 2014-07, Vol.20 (14), p.3660-3671

2014

Volltextzugriff (PDF)

Abstract CT088: Final results of the Phase I study of nivolumab in combination with CIMAvax, an epidermal growth factor(EGF)-depleting immunotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Focus on biomarker analyses

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT088-CT088

2019

Volltextzugriff (PDF)

Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis

The Journal of experimental medicine, 2004-03, Vol.199 (5), p.649-659

2004

Volltextzugriff (PDF)

Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy

Journal of immunotherapy (1997), 2017-10, Vol.40 (8), p.289

2017

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(42)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Oncology
(16)
Humans
(15)
Immunology
(14)
Female
(10)
Cancer Vaccine
(8)
Male
(8)
Middle Aged
(7)
T Cells
(7)
Immunotherapy
(6)
Itolizumab
(6)
Monoclonal Antibodies
(6)
Lung Neoplasms - Immunology
(5)
Medicine, Research & Experimental
(5)
Research & Experimental Medicine
(5)
Aged
(4)
Antineoplastic Agents
(4)
Biological And Medical Sciences
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti–Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non–Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab

Nimotuzumab: beyond the EGFR signaling cascade inhibition

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients

Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model

CIMAvax-EGF: Toward long-term survival of advanced NSCLC

Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)

Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

Abstract CT088: Final results of the Phase I study of nivolumab in combination with CIMAvax, an epidermal growth factor(EGF)-depleting immunotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Focus on biomarker analyses

Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis

Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy

Suchergebnisse filtern